A service evaluation of the impact of adoption of JBDS guidelines for the management of glucose during labour and birth in women with diabetes

UMESH DASHORA, SUHAIL AHMED, IRENE BOSSMAN, KO KO AUNG, ERWIN CASTRO, PARIASAMY SATHISKUMAR

Abstract
Aims: The aim of this retrospective observational study was to report on the impact of adopting the Joint British Diabetes Society for Inpatients (JBDS-IP) guidelines on the achievement of targets recommended by the National Institute for Health and Care Excellence (NICE) and the maternal and neonatal outcomes.

Methods: We analysed case records of pregnant women with diabetes who delivered in the period between November 2017 and October 2018 from our data base ‘Euroking’ (Wellbeing Software Ltd, Mansfield). Data were collected in relation to the availability of a dedicated prescription chart in the notes, capillary blood glucose (CBG) monitoring, use of variable rate intravenous insulin infusion (VRIII), maintenance of CBG targets within 4.0–7.0 mmol/L, maternal hypoglycaemia during labour when on VRIII and neonatal hypoglycaemia.

Results: Sixty women with diabetes in our database delivered during this period. Thirty-six (60%) were monitored with hourly CBG monitoring and 30 (50%) achieved CBG levels within the NICE recommended target range. Only five women (8.3%) were started on VRIII. There was no maternal hypoglycaemia in the VRIII group. One baby (1.7%) developed mild neonatal hypoglycaemia.

Conclusion: Adoption of JBDS guidelines contributed to 60% of women with diabetes receiving complete CBG monitoring, of whom 70% achieved the NICE recommended target of 4.0–7.0 mmol/L during labour and birth. Repeat CBG measurements before starting VRIII, strict adherence to clear JBDS guidelines and protocols, daily review by the diabetes team during the working week and appropriate use of VRIII was associated with good maternal and neonatal outcomes.

Key words: JBDS, NICE, targets, diabetes, delivery, neonatal, hypoglycaemia, outcome

Introduction
Infants born to mothers with diabetes have higher morbidity, including the risk of neonatal hypoglycaemia, and many of these adverse outcomes are unaffected by pre-pregnancy care. Neonatal hypoglycaemia is thought to be secondary to beta cell hyperplasia in the infant pancreas following maternal hyperglycaemia in pregnancy. It is not uncommon. It may have significant consequences on the neural development of the child, which may become apparent at a later age and needs to be prevented, identified and promptly treated. It has been hypothesised that the last 18 hours in utero is important to prevent neonatal complications, even in women with good glycaemic control during pregnancy.

The National Institute for Health and Care Excellence (NICE) recommends maintaining maternal blood glucose between 4.0 and 7.0 mmol/L during labour and birth to reduce neonatal hypoglycaemia. The use of a combined insulin and glucose infusion to maintain maternal blood glucose in the target range has been suggested. However, some studies have questioned the definition of neonatal hypoglycaemia and its relationship to maternal hyperglycaemia. They also raised concerns that maintaining tight glycaemic control in the range of 4.0–7.0 mmol/L may increase maternal hypoglycaemia and resource burden without any clear reduction in neonatal hypoglycaemia. However, the relaxed targets in some of these studies (3.3–6.7 mmol/L) are tighter than NICE recommended targets (4.0–7.0 mmol/L). The evidence of a safer relaxed target therefore is not clear.

We adopted Joint British Diabetes Society (JBDS) guidelines for diabetes control during labour and birth in November 2017. As per the guidelines, we performed capillary blood glucose (CBG) monitoring hourly from the onset of labour in all women with any type of diabetes. Variable rate intravenous insulin infusion (VRIII)
was started in women only if two consecutive CBG levels were >7.0 mmol/L or if the woman had type 1 diabetes. The VRIII scale was adjusted to keep CBG between 4.0 and 7.0 mmol/L, as recommended by NICE.15,16

The current retrospective observational cohort study was undertaken to investigate the adherence, feasibility and effectiveness of our new protocol based on JBDS guidelines in reaching NICE recommended targets and the resultant impact on neonatal hypoglycaemia. We also wanted to see if VRIII use increased the risk of maternal hypoglycaemia. We had a high incidence of neonatal hypoglycaemia and some maternal hypoglycaemia on VRIII in our previous study17 and we were keen to see the impact of the revised approach on these two outcomes.

Methods
A list of mothers with diagnosed diabetes mellitus (gestational, type 1 and type 2) who delivered during the period from November 2017 to October 2018 was compiled from the obstetric Euroking database (Wellbeing Software Ltd, Mansfield, UK).

Case records were analysed for the type of diabetes, insulin use and if there were appropriate plans for labour with VRIII and CBG forms in their files. The JBDS guidelines-driven plan that we started using in September 2017 is shown in Figure 1, and was slightly different from the local protocol that we used last time. Basal insulin when used is continued during labour, and meal time insulin is continued as long as CBG levels are within the target range. Once the patient is in established labour and is either known to have type 1 diabetes or the CBG is >7.0 mmol/L on two consecutive occasions (rather than a single reading as in the previous protocol) or is not reliably eating and drinking, VRIII is started. Once VRIII is started, basal insulin is continued and meal time insulin is withheld.

The records were also analysed for CBG levels during labour, appropriate use of VRIII, type of delivery, maternal hypoglycaemia during VRIII and the incidence of neonatal hypoglycaemia. Fisher’s exact test was used to determine statistical significance.

CBG monitoring was considered incomplete if any readings were missing from the chart, except if the delivery was within half an hour of admission. Maternal hypoglycaemia and neonatal hypoglycaemia were defined as a level below 4.0 mmol/L and 2.6 mmol/L, respectively, for the purpose of this study.

Results
We identified 60 women with diabetes from the database who delivered between November 2017 and October 2018. Fifty-seven women had gestational diabetes, two had type 2 diabetes and one had type 1 diabetes (see Tables 1 and 2). The treatment included diet alone (n=18), oral medications (n=17), insulin (n=11) or a combination of insulin with oral drugs (n=14). Fifty-five were Caucasians, three were of Indian extraction and two were of Chinese extraction. Thirty-six women had no obstetric complications but six had macrosomia and 15 had polyhydramnios. Twenty-seven women had a normal vaginal delivery but 14 had elective caesarean section (CS), five had an emergency CS and 14 needed forceps delivery. One delivery was pre-term. Fifty-eight women (97%) had an appropriate prescription plan and 54 (90%) had a CBG monitoring chart in their notes before admission. All women were reviewed by the diabetes team daily during the working week after admission.

CBG monitoring
Forty-two women (70%) received some CBG monitoring as per protocol. In 18 cases (30%) we could not find any documentation of CBG records. Of those monitored (n=42), 36 (86%) had complete hourly CBG monitoring and six (14%) had at least one reading missed. In two cases the CBG was considered satisfactory and therefore classed as complete even when there was no CBG record due to quick deliveries within half an hour of hospital admission. Thirty (50%) women remained in the NICE

| Table 1 Comparison of our studies on glycaemic control during labour and birth with n (rounded up %) if applicable: baseline characteristics |
|---|---|---|
| **Period of study** | **July 2014 to June 2015** | **Nov 2017 to October 2018** |
| **Protocol used** | Local | JBDS-IP |
| **Women who delivered over the period as per Euroking database (actual number higher)** | 51 (100) | 60 (100) |
| **Trigger in the protocol for starting VRIII in labour** | Hourly CBG during labour and VRIII started if one reading >7.0 mmol/L | Hourly CBG during labour and start VRIII if 2 consecutive readings >7.0 mmol/L |
| **Treated with diet** | 10 (20) | 18 (30) |
| **Treated with oral drugs** | 6 (12) | 17 (28) |
| **Treated with insulin** | 25 (50) | 11 (18) |
| **Treated with insulin + oral drugs** | 10 (20) | 14 (23) |
| **Macrosomia** | 15 (29) | 6 (10) |
| **Polyhydramnios** | 6 (12) | 15 (25) |

CBG, capillary blood glucose; VRIII, variable rate intravenous insulin infusion.
Figure 1. Prescription chart based on JBDS guidance and used in our Trust

**Intravenous Insulin Prescription and Fluid Protocol**

**PREGNANCY AND LABOUR ONLY**

For use during pregnancy and labour for **ALL** patients receiving Variable Rate Intravenous Insulin Infusion (VRIII)

- **NEVER** use an IV syringe to draw up insulin
- **ALWAYS** draw up insulin using an insulin syringe
- **ALWAYS** continue subcutaneous basal insulin

**Dosing Algorithm**

<table>
<thead>
<tr>
<th>CBG Levels (mmol/L)</th>
<th>Infusion Rate (Units/hr = ml/hr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;4</td>
<td>STOP INSULIN FOR 20 MINUTES</td>
</tr>
<tr>
<td>4.0 - 5.5</td>
<td>0.2</td>
</tr>
<tr>
<td>5.6 - 7.0</td>
<td>0.5</td>
</tr>
<tr>
<td>7.1 - 8.5</td>
<td>1.0</td>
</tr>
<tr>
<td>8.6 - 11.0</td>
<td>1.5</td>
</tr>
<tr>
<td>11.1 - 14.0</td>
<td>2.0</td>
</tr>
<tr>
<td>14.1 - 17.0</td>
<td>2.5</td>
</tr>
<tr>
<td>17.1 - 20.0</td>
<td>3.0</td>
</tr>
<tr>
<td>&gt;20.1</td>
<td>4.0</td>
</tr>
</tbody>
</table>

**Algorithm Guide**

- **ALL** women with diabetes should have Capillary Blood Glucose (CBG) testing hourly in established labour or at least once on admission for induction of labour or elective C-Section
- Start VRIII and Fluids if two consecutive CBGs > target (see below) or at the start of established labour if the woman has type 1 diabetes

**Algorithm 1**

**Algorithm 2**

**Algorithm 3**

**No patient starts here without diabetes or medical review**

If the woman is not achieving targets with these algorithms, contact the diabetes team (out of hours: Medical SpR on call)

**Target CBG Levels 4-7 mmol/l**

Check CBG every hour whilst on IV insulin

- **Move Up** if the CBG is > 7 mmol/l and has not reduced in 1 hour
- **Move Down** (when using higher algorithms) if CBG is < 4 mmol/l

**Intravenous Substrate Fluid**

Date: 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00 23:00 24:00

**Hypoglycaemia Management**

**Gestational Diabetes:**

Stop VRIII and IV Substrate Fluid regime once placenta is delivered

**Type 1 DM and Insulin Treated Type 2 DM:**

Reduce the rate of VRIII by half once placenta is delivered

Contact diabetes team to review ongoing insulin requirements

**Capillary Blood Glucose Monitoring (hourly after starting infusion)**

**Maintain IV infusion for 30 minutes after re-starting original insulin regime—IV insulin has a 5 minute half life**
**Figure 1.** Prescription chart based on JBDS guidance and used in our Trust (continued)

<table>
<thead>
<tr>
<th>Ward</th>
<th>Consultant</th>
<th>Admission Date</th>
</tr>
</thead>
</table>

**DIABETES CARE PLANNING DOCUMENT**

For use to communicate care plans for ALL patients with diabetes during and after pregnancy

Please complete ALL required information

To be completed by the Diabetes Team

**Patient Details**

Please attach addressograph label

<table>
<thead>
<tr>
<th>Surname</th>
<th>First Name</th>
<th>NHS Number</th>
<th>Date of Birth/Age</th>
</tr>
</thead>
</table>

**Antenatal Information**

**Type of Diabetes**

- [ ] Type 1 DM
- [ ] Type 2 DM
- [ ] Gestational DM

- Age at diagnosis
- Age at diagnosis
- Diagnosed:
  - [ ] 1 OGTT: Date:
  - Fasting: mmol/L
  - Fasting: mmol/L
  - 2 hours: mmol/L

**Pre-Pregnancy Diabetes Medications**

<table>
<thead>
<tr>
<th>Medication</th>
<th>Dose</th>
<th>Time</th>
</tr>
</thead>
</table>

**HbA1c Record**

- Baseline: Date: Value: mmol/mol
- Additional HbA1c: Date: Value: mmol/mol
- Notes: Date: Value: mmol/mol
- Date: Value: mmol/mol
- Date: Value: mmol/mol

**Complications Developed or Exacerbated by Pregnancy**

**Delivery Dates**

- Expected Date of Delivery
- Date for IOL
- Date for C-Section

**Postnatal Plan**

**Proposed Post-Pregnancy Diabetes Medications**

<table>
<thead>
<tr>
<th>Medication</th>
<th>Dose</th>
<th>Time</th>
</tr>
</thead>
</table>

**Discussed with Patient**

<table>
<thead>
<tr>
<th>Issues:</th>
<th>Yes</th>
<th>No</th>
<th>Date Discussed</th>
</tr>
</thead>
</table>
- Contraception/plans for further pregnancy
- Arrangement for ongoing diabetes care
- OGTT arrangement
- Lifestyle modifications

**Completed by:**

**Sig:**

**Postnatal CG Monitors Monitoring**

For up to 24 hours post delivery

**Targets:**

- Pre-Meals <7 mmol/L
- Post-Meal <11 mmol/L

<table>
<thead>
<tr>
<th>Date</th>
<th>Pre-breakfast</th>
<th>1 hr after breakfast</th>
<th>Pre-lunch</th>
<th>1 hr after lunch</th>
<th>Pre-evening meal</th>
<th>1 hr after evening meal</th>
<th>Pre-bed</th>
</tr>
</thead>
</table>

**Maternal Outcomes**

**Postnatal Outcomes (tick that applies)**

<table>
<thead>
<tr>
<th>Delivery</th>
<th>Tick that applies</th>
<th>Complications</th>
<th>Tick that applies</th>
</tr>
</thead>
</table>
- Normal
- Assisted/forceps
- C-Section

- Stilbirth
- Neonatal jaundice
- Baby weight over 4 kg
- Neonatal hypoglycaemia
- Admission to NICU
- Shoulder dystocia
- Birth defects
recommended target range of 4.0–7.0 mmol/L and 12 (20%) could not be maintained within the target range. Of the 30 women whose CBG remained in the target range, nine were on diet alone whereas five needed addition of metformin, seven were on insulin alone and nine needed metformin in combination with insulin. The mean (SD) basal insulin dose was 7 (9.8) units with a range of 0–38 units and the mean (SD) bolus insulin dose was 3 (5.7) units with a range of 0–20 units. The highest dose of insulin in this group was 45 units. Poor monitoring was more common in women who had elective CS compared with delivery by other means (p=0.0013, significant at 0.05 level by Fisher’s exact test). Six women who delivered normally, eight who had elective CS and four who had forceps delivery had no records of CBG monitoring and all delivered within 2 hours of presentation. There was no relationship between the completeness of CBG monitoring and whether or not the women were treated with insulin.

Women who received or missed VRIII during delivery
With the adoption of JBDS guidance, only five women (8.3%) were started on VRIII. Four women had gestational diabetes and one had type 1 diabetes. Four women had two consecutive CBG readings of >7.0 mmol/L (range 9.0–11.0 mmol/L) and received VRIII appropriately. In one woman VRIII was started at a CBG level of 5.1 mmol/L as steroids were given for prematurity (as per JBDS protocol). VRIII was able to maintain CBG levels satisfactorily – that is, either within target range or with improving levels – in all cases except if delivery occurred in such a short period that a change in VRIII scale was neither possible nor needed. There was no incidence of neonatal hypoglycaemia in the babies born to any of these women. Two women missed VRIII after two consecutive CBG readings of >7.0 mmol/L due to quick deliveries within an hour and the babies did not have neonatal hypoglycaemia. Three women had only one CBG read-

Table 2: Comparison of our studies on glycaemic control during labour and birth with n (rounded up % of the cohort or the group) if applicable: observations/outcomes

<table>
<thead>
<tr>
<th>Period of study (n)</th>
<th>July 2014 to June 2015 (n=51)</th>
<th>Nov 2017 to October 2018 (n=60)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daily review by diabetes team during working week</td>
<td>39 (76)</td>
<td>60 (100)</td>
</tr>
<tr>
<td>Some CBG monitoring</td>
<td>27 (53)</td>
<td>42 (70)</td>
</tr>
<tr>
<td>Complete CBG monitoring</td>
<td>23 (45)</td>
<td>36 (60)</td>
</tr>
<tr>
<td>Women with CBG in target out of women monitored</td>
<td>7 (26)</td>
<td>30 (71)</td>
</tr>
<tr>
<td>Elective CS</td>
<td>17 (33)</td>
<td>14 (23)</td>
</tr>
<tr>
<td>Women delivered by elective CS who received complete CBG monitoring</td>
<td>3 (18)</td>
<td>3 (21)</td>
</tr>
<tr>
<td>Delivery by modes other than elective CS</td>
<td>34 (67)</td>
<td>46 (77)</td>
</tr>
<tr>
<td>Women delivered by modes other than elective CS who received complete hourly CBG monitoring</td>
<td>18 (53)</td>
<td>33 (72) p&lt;0.0013 vs women delivered by elective CS</td>
</tr>
<tr>
<td>Women who were considered eligible for VRIII</td>
<td>14 (27)</td>
<td>5 (8)</td>
</tr>
<tr>
<td>VRIII missed inappropriately</td>
<td>5 (10)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Women who received VRIII</td>
<td>9 (64)</td>
<td>5 (100)</td>
</tr>
<tr>
<td>VRIII started appropriately</td>
<td>7 (78)</td>
<td>5 (100)</td>
</tr>
<tr>
<td>VRIII started inappropriately</td>
<td>2 (22)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>VRIII effective in controlling CBG satisfactorily</td>
<td>2 (22)</td>
<td>5 (100)</td>
</tr>
<tr>
<td>Women on VRIII who delivered babies with neonatal hypoglycaemia</td>
<td>4 (44)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Neonatal hypoglycaemia in babies born to women who inappropriately missed VRIII</td>
<td>4 (80)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Women on VRIII who developed maternal hypoglycaemia</td>
<td>2 (22)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Women with GDM</td>
<td>41 (80)</td>
<td>57 (95)</td>
</tr>
<tr>
<td>Women with GDM who received VRIII</td>
<td>6 (15)</td>
<td>4 (7)</td>
</tr>
<tr>
<td>Women with type 1 diabetes</td>
<td>5 (10)</td>
<td>1 (2)</td>
</tr>
<tr>
<td>Women with type 1 diabetes who received VRIII</td>
<td>2 (40)</td>
<td>1 (100)</td>
</tr>
<tr>
<td>Women with type 2 diabetes</td>
<td>5 (10)</td>
<td>2 (3)</td>
</tr>
<tr>
<td>Women with type 2 diabetes who received VRIII</td>
<td>1 (20)</td>
<td>1 (50)</td>
</tr>
<tr>
<td>Neonatal hypoglycaemia in the whole cohort</td>
<td>24 (47)</td>
<td>1 (2)</td>
</tr>
<tr>
<td>Neonatal hypoglycaemia in GDM group</td>
<td>18 (35)</td>
<td>1 (2)</td>
</tr>
</tbody>
</table>

CBG, capillary blood glucose; CS, caesarean section; GDM, gestational diabetes; VRIII, variable rate intravenous insulin infusion
ing >7.0 mmol/L and would have been put on VRIII according to the old guidance but did not get VRIII according to the JBDS protocol. The babies of these women did not have neonatal hypoglycaemia. No woman on VRIII developed maternal hypoglycaemia.

**Woman who delivered baby with neonatal hypoglycaemia**

Only one baby (1.7%) developed mild neonatal hypoglycaemia with a CBG level of 2.3 mmol/L born to a 29-year-old mother, gravida 1, Caucasian, with gestational diabetes who had no complications during pregnancy and was on insulin. The CBG improved with breast feeding. There was no record of HbA1c. She had elective CS. She did not have her CBG checked before or during section and no VRIII was started. One baby out of 60 had no CBG record.

**Women who developed maternal hypoglycaemia during labour**

Although no woman developed hypoglycaemia on VRIII, 12 women (20%) had 22 episodes of minor hypoglycaemia (corrected without the need of third party assistance) picked up on hourly CBG monitoring. One mother had a CBG of 2.4 mmol/L 30 minutes after delivery and another one had a CBG of 3.7 mmol/L after CS. Three of these women were only diet treated, five were on metformin, four were receiving insulin treatment and two were on metformin and insulin. Many of these episodes were asymptomatic, although as it was a retrospective review of case notes an accurate record of symptoms was not available. There were four readings <4.0 mmol/L in one woman on CBG monitoring during labour at 2, 3, 4 and 5 hours after being in established labour. Two other women each had three readings <4 mmol/L. All except one of the CBG readings in the cohort were between 3.0 and 4.0 mmol/L. All episodes were easily treated as per hospital protocol.

**Discussion**

This study has shown that, with the adoption of the JBDS guidelines for the management of diabetes during labour and birth, we had a high proportion of women in established labour with complete CBG monitoring and achievement of NICE recommended target CBG levels, very few women needing VRIII and a very low incidence of neonatal hypoglycaemia.

**CBG monitoring**

It is difficult for midwives to maintain hourly CBG monitoring until the end of labour. NICE has suggested a staffing level of one midwife for each mother in labour; however, this can be difficult to achieve in some hospitals. In our hospital it is not uncommon for midwives to care for two women at a time, at least immediately after admission. Some of the CBG measurements might have been misplaced and therefore recorded as not done. In our study, 36 (60%) women received complete CBG monitoring from the onset of labour to birth. A significant number of patients had quick deliveries due to either elective CS (8 women) or quick deliveries within 2 hours of presentation to hospital (10 women). We could not find any records of CBG monitoring in these 18 women. This group can explain the monitoring gap we picked up in our study. As the CS patients are not in labour, the hourly monitoring is delayed until the patient is ready to be taken to theatre. Similar findings were noted in our earlier study when women who delivered by CS did not have CBG monitored.17 Early start of monitoring may pick up glucose abnormalities in some of these patients. Subsequent early and appropriate action has the potential to maintain patients within the NICE recommended target. This in turn has the potential to reduce neonatal hypoglycaemia and other complications. The only baby who had neonatal hypoglycaemia in the current study was delivered by elective CS, and we could not find any evidence of CBG monitored in the woman.

Of those women where any monitoring was available, 30 (71%) had their CBG within the target range of 4.0–7.0 mmol/L compared with only seven (26%) in our previous study. This might be partly due to the new protocol, diabetes team review and the education that accompanied it.

**Use of VRIII**

In the current study only five women (8.3%) needed VRIII compared with nine (17.6%) in our previous study.17 The JBDS guidelines suggest two consecutive CBG levels to be >7.0 mmol/L to trigger VRIII. A similar watchful wait approach has been described in some other studies.19 This approach helped avoid VRIII in five women, all of whom either had a second reading which was lower than the cut-off value of 7.0 mmol/L (3 women) or were delivered within an hour of two CBG levels being high (2 women), and therefore they did not need or get VRIII. NICE guidelines provide an excellent framework for managing patients with diabetes during delivery, but in some cases the decision to defer or avoid VRIII may be entirely appropriate, particularly if the delivery is imminent. After adopting the JBDS guidance we did not encounter any women who missed VRIII inappropriately.

Although our prescription chart now clarifies the need to start VRIII and monitor CBG every hour in all patients with pre-existing type 1 diabetes, our woman with type 1 diabetes did not get adequate monitoring and this issue may need addressing in the educational sessions with midwives. Similar difficulties with monitoring have been noted in other studies.19 Our patient who was sent to theatre without a prior CBG highlights a safety breach and the ongoing need for education to the obstetric staff in hospitals. Unfortunately, the baby delivered to this woman was the only one who had mild neonatal hypoglycaemia.

In the current study all the women who received VRIII had CBG levels either within the target or had a satisfactory trend. Adjustment of the VRIII scale was therefore not needed. There was no incidence of maternal or neonatal hypoglycaemia in this group. This is in contrast to our previous study when only two women (22%) on VRIII achieved the CBG target, two (22%) had maternal hypoglycaemia and four (44%) delivered babies with neonatal hypoglycaemia. Effective use of continuous glucose monitoring and continuous subcutaneous insulin infusion may
be other options to control CBG levels in a tight target range without causing significant hypoglycaemia. However, this has not been studied in detail yet.\textsuperscript{20, 21}

### Neonatal hypoglycaemia

Neonatal hypoglycaemia is not clearly defined in the literature, with values defining it from 1.6–2.2 mmol/L to 2.5–2.6 mmol/L.\textsuperscript{22} In our group, hospital policy defined it as <2.6 mmol/L at the time of the study. The most recent publication involving large numbers (n=17,094) suggests that the normal glucose threshold could be 2.2 mmol/L for the 90th centile and 1.9 mmol/L for the 95th centile in the neonate.\textsuperscript{23} Routine measurement of neonatal blood glucose shows that 5% of apparently normal neonates have CBG levels <1.7 mmol/L in the first few hours of life.\textsuperscript{24} Many experts, however, feel that symptomatic hypoglycaemia and a measured glucose of <2.5 mmol/L should be managed aggressively.\textsuperscript{25} Others have recommended intravenous glucose for infants with glucose <1.4 mmol/L.\textsuperscript{26}

Of 24 studies reviewed recently, 19 specifically looked for a relationship between maternal glucose during labour and neonatal hypoglycaemia. In 10 of these studies there was an inverse relationship, with a similar trend in another three and six found no relationship.\textsuperscript{27} The authors believe that a target CBG of 4–6 mmol/L can be used safely and results in a low rate of neonatal hypoglycaemia.\textsuperscript{27} Some other authors did find an association with neonatal hypoglycaemia, but only at a threshold of maternal CBG >8 mmol/L. Interestingly, there was no increase in neonatal hypoglycaemia when CBG levels were kept below 8 mmol/L.\textsuperscript{11}

In our study only one baby (1.7%) had neonatal hypoglycaemia compared with 24 (47%) in our previous study and another study.\textsuperscript{17, 28} Women with gestational diabetes comprised the largest and most comparable group in both studies but, even in that group, 18 women (35%) delivered babies with neonatal hypoglycaemia in the previous study. There was no neonatal hypoglycaemia to any women with known CBG levels in our study. A similar rate of overall neonatal hypoglycaemia (near 0%) has been described in some other studies.\textsuperscript{17} Neonatal hypoglycaemia rates reported in the literature range from 0%\textsuperscript{21, 29} to 69%.\textsuperscript{30} In one study 43% of babies had neonatal hypoglycaemia even when the mothers were maintained in the target range.\textsuperscript{19} This may be because neonatal hypoglycaemia is caused not only by hyperinsulinaemia during labour but also during pregnancy, especially when the diabetes control is not tight.\textsuperscript{5} Indeed, the four women in our previous study who had neonatal hypoglycaemia in spite of VRIII exhibited indicators of poor control during pregnancy (macrosomia, polyhydramnios and high HbA\textsubscript{1c}).\textsuperscript{17} Moreover, neonatal hypoglycaemia is commonly associated with maternal diabetes,\textsuperscript{31} but can also be the result of other reasons like pituitary adrenal and other metabolic causes.\textsuperscript{32, 33}

### Maternal hypoglycaemia

In our study we did not see any maternal hypoglycaemia in women who received VRIII. In several studies, maternal hypoglycaemia was a recognised complication when trying to keep CBG levels at 4.0–7.0 mmol/L.\textsuperscript{34–38} In our previous study, two women (22.2%) who used VRIII developed hypoglycaemia with CBG <4 mmol/L compared with none of those who did not require VRIII (p<0.02). Maternal hypoglycaemia can be as high as 56% with tighter targets of 4.0–6.5 mmol/L.\textsuperscript{30} Some studies have reported a reduction in maternal hypoglycaemia from 40% to 22.2% when the target CBG is relaxed.\textsuperscript{39, 40} This is similar to the minor maternal hypoglycaemia noted in our study which was promptly and easily treated. The low incidence of hypoglycaemia in the current study in spite of a tight target of 4–7 mmol/L, even in women with VRIII, is reassuring and may be partly because of more monitoring and effective adjustment of glucose and insulin arms of infusion by the staff, but requires more resources.

An editorial in Anaesthesia warns against maternal hypoglycaemia in women on VRIII and suggests targeting CBG at 6.0–8.0 mmol/L.\textsuperscript{12} The debate on tighter versus relaxed CBG monitoring frequency as well as target continues. This has raised questions about the possible benefit or harm from national guidance.\textsuperscript{41–43} In our current study we found that the implementation of JBDS guidance was associated with safe maternal outcomes for women with diabetes delivering in our hospital, although 20% minor maternal hypoglycaemia is still a concern. Further research is, however, urgently needed to confirm whether relaxation in CBG targets and frequency is possible without any deleterious effect on the neonatal outcomes. The recent suggestion is that, if we adjust for all the other neonatal factors, intrapartum glucose is not significantly associated with neonatal hypoglycaemia in all types of diabetes and therefore a relaxed approach is worth investigating,\textsuperscript{13} and that antenatal diabetes control may be more important than intrapartum glucose control.\textsuperscript{44} In patients who are undergoing regional analgesia or anaesthesia, CBG monitoring every half an hour and a more relaxed target has been suggested as an option in the JBDS guidance.\textsuperscript{15}

### Limitations

There are some limitations of this study. The true number of women with diabetes who delivered in our hospital in this period is higher than the number we were able to obtain from our Euroking database. Most of the women had gestational diabetes, with only one woman with type 1 diabetes and two with type 2 diabetes. We might have missed some women with pre-existing diabetes in both studies, but perhaps more in the current study. We have presented our findings from the previous study (Tables 1 and 2) as an observation only, and a direct comparison is not possible due to differences in the number of women with pre-existing diabetes as well as services received by them. The data on CBG were missing for a number of women in our study. The near absence of neonatal hypoglycaemia in our current study may partly reflect advancement in treatment, care, support and education available to mothers this time compared with our previous study and may not be attributable solely to the adoption of JBDS guidance. Indeed, more women were reviewed by the diabetes team on each working day of the week in the present study compared with the previous one (100% vs 76%).
Key messages

- National Institute of Health and Care Excellence (NICE) recommends hourly capillary blood glucose (CBG) monitoring in women with diabetes during established labour and birth and maintaining CBG levels between 4.0 and 7.0 mmol/L.
- We adopted the Joint British Diabetes Societies (JBDS) guidelines to achieve these recommendations.
- Thirty-six women (60%) received hourly CBG monitoring and 30 (50%) achieved CBG levels in the NICE recommended target range.
- Only five women (8.3%) needed variable rate intravenous insulin infusion (VRIII).
- There was only one baby with neonatal hypoglycaemia (1.7%).
- Poor monitoring was seen more often in women who delivered by elective caesarean section compared with other modes of delivery (p<0.0013).
- Systems, prompts and clear guidelines formed the basis of effective and safe achievement of NICE recommended target blood glucose during delivery and birth.

Regular daily review by the diabetes team might have helped continuous on-site education of maternity staff in addition to troubleshooting and reinforcement of protocols more effectively.

Summary and recommendations

With the adoption of JBDS guidelines, 60% of women with diabetes in established labour received complete hourly CBG monitoring of whom 71% achieved the NICE recommended target levels. VRIII was used in only 8.3% of women and neonatal hypoglycaemia was seen in only 1.7% of babies. There was no maternal hypoglycaemia in women who needed VRIII.

Maintaining CBG levels in mothers at 4–7 mmol/L during labour continues to remain difficult. Repeating CBG monitoring when the first CBG reading is >7 mmol/L and starting VRIII only if two consecutive readings are >7 mmol/L helped us avoid excessive use of VRIII but, at the same time, this approach was able to maintain appropriate metabolic control which might have contributed to low levels of neonatal hypoglycaemia.

Additional education should be in place to achieve, document and record CBG monitoring appropriately, especially in women who undergo CS. One-to-one staffing and regular education of all the staff involved is crucial. More randomised studies are urgently needed to ascertain the exact targets for this group of patients.

Conflict of interest None.

Funding None.

References
